Dogwood Therapeutics to Share Q3 Financial Results
ATLANTA, Oct. 31, 2024 -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX), previously known as Virios Therapeutics, Inc., is set to unveil its financial results for the third quarter of 2024 on Thursday, November 7, 2024. The report will be available before the market opens, offering investors a glimpse into the company’s performance and strategic direction.
Details of the Upcoming Call
On the same day, management will conduct a live webcast alongside a conference call at 8:30 a.m. ET to discuss the results. This is a fantastic opportunity for shareholders and market participants to hear directly about the company’s progress and future plans.
A Close Look at Dogwood Therapeutics
Dogwood Therapeutics (NASDAQ: DWTX) focuses on developing innovative therapies aimed at addressing pain and fatigue-related conditions. The company's research pipeline boasts two distinct mechanistic platforms: a non-opioid analgesic program and an antiviral program.
Innovative Research and Development
At the forefront of their non-opioid analgesic program is a novel treatment known as Halneuron, a voltage-gated sodium channel blocker. This promising candidate is poised to offer significant relief for patients experiencing pain associated with various conditions, including general cancer-related pain and chemotherapy-induced neuropathic pain (CINP). Interim data from the pending Phase 2 CINP study is anticipated in the latter half of 2025.
Advancements in Viral Treatment
In addition, Dogwood's antiviral program features unique combinations designed to target herpes virus reactivations. These include the proprietary formulations IMC-1 and IMC-2, which combine nucleoside analogs and the anti-inflammatory medication celecoxib. This program aims to tackle diseases thought to be linked to dormant herpes viruses, such as fibromyalgia (FM) and Long-COVID (LC). Top-line data from the ongoing Phase 2 trial for IMC-2 is expected shortly.
Future Endeavors and Clinical Trials
IMC-1 is also gearing up for Phase 3 trials focused on fibromyalgia, indicating Dogwood’s commitment to bringing new therapies to market. The company is actively seeking partnerships to advance this pivotal project.
Stay Connected with Dogwood Therapeutics
To keep up with the latest developments, investors and interested parties can follow Dogwood Therapeutics through its various platforms.
Email Alerts and Social Media
For instant updates, sign up for email alerts via their investor relations site. Followers can also connect with the company through its social media channels:
- LinkedIn: https://www.linkedin.com/company/dogwoodther/
- Twitter: https://twitter.com/dogwoodther
- Facebook: https://www.facebook.com/dogwoodther
Frequently Asked Questions
What is Dogwood Therapeutics?
Dogwood Therapeutics is a clinical-stage biopharmaceutical company focused on creating new medications for pain and fatigue-related disorders.
When will Dogwood Therapeutics report its Q3 financial results?
The company will report its Q3 financial results on November 7, 2024, before the market opens.
How can I access the conference call?
You can access the call by dialing 888-506-0062 for domestic calls and 973-528-0011 for international calls. Use the access code 838895.
What are the main projects Dogwood is working on?
Dogwood is focusing on a non-opioid analgesic program with the candidate Halneuron, and an antiviral program with products IMC-1 and IMC-2 for conditions related to herpes viruses.
How can I stay updated with Dogwood Therapeutics?
You can follow the company on LinkedIn, Twitter, and Facebook, as well as sign up for email alerts on their investor relations page.
